Update on the Systemic Treatment of Malignant Melanoma

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 4, 2004, Pages 33-37

  Lawson, David H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANCER VACCINE; CISPLATIN; DACARBAZINE; DEPSIPEPTIDE; FLUOROURACIL; GANGLIOSIDE; HISTAMINE; INTERLEUKIN 2; LENALIDOMIDE; PAROXETINE; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SORAFENIB; SYNTHETIC PEPTIDE; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ALLOIMMUNITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG APPROVAL; DRUG MEGADOSE; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; MELANOMA; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; STANDARD;

EID: 2342550167     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.02.014     Document Type: Conference Paper

References (43)

1. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
2. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
3. Morton DL: Lymphatic mapping and sentinel lymphadenectomy for melanoma: Past, present, and future. Ann Surg Oncol 8:22S-28S, 2001 (suppl)
4. Reintgen DS: Metastatic melanoma to regional lymph nodes. In Vivo 14:213-220, 2000
5. Chao C, McMasters KM: Update on the use of sentinel node biopsy in patients with melanoma: who and how. Curr Opin Oncol 14:217-220, 2002
6. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
7. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444-2458, 2000
8. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
9. Kilbridge KL, Cole BF, Kirkwood JM, et al: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20:1311-1318, 2002
10. Kirkwood JM, Bender C, Agarwala S, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002
11. Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961-966, 2001
12. Kirkwood JM, Richards T, Zarour HM, et al: Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101-1112, 2002
13. Buzaid AC, Atkins M: Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 7:2611-2619, 2001
14. Hsueh EC, Essner R, Foshag LJ, et al: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549-4554, 2002
15. Agarwala S: Interferon and adjuvant therapy: Cutaneous Melanomain Balch CM. Quality Medical Publishing, St Louis, MO, 2003
16. Spitler LE, Grossbard ML, Ernstoff MS, et al: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18: 1614-1621, 2000
17. Allen PJ, Coit DG: The surgical management of metastatic melanoma. Ann Surg Oncol 9:762-770, 2002
18. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
19. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant metanoma. J Clin Oncol 18:158-166, 2000
20. Atkins MB: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplastin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22:708, 2003 (abstr)
21. Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228:307-319, 1998
22. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
23. Guirguis LM, Yang JC, White DE, et al: Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 25:82-87, 2002
24. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
25. Yang JC, Sherry RM, Steinberg SM, et al: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132, 2003
26. Agarwala S: Phase II trial of high-dose bolus IL-2 in patients with metastatic melanoma (mm) who have previously failed biochemotherapy (BCT). Proc Am Soc Clin Oncol 22:724, 2003 (abstr)
27. Weinreich DM, Rosenberg SA: Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. J Immunother 25:185-187, 2002
28. Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24:287-293, 2001
29. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
30. Agarwala SS, Glaspy J, O'Day SJ, et al: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20:125-133, 2002
31. Hwu WJ, Krown SE, Menell JH, et al: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356, 2003
32. Hwu WJ: Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from malignant melanoma. Proc Am Soc Clin Oncol 22:720, 2003 (abstr)
33. Margolin K, Atkins B, Thompson A, et al: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002
34. Mori Y, Kondziolka D, Flickinger JC, et al: Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42:581-589, 1998
35. Yu C, Chen JC, Apuzzo ML, et al: Metastatic melanoma to the brain: Prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52:1277-1287, 1998
36. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733, 2000
37. Flaherty L: Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol 22:710, 2003 (abstr)
38. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728, 2002
39. Kirkwood JM: E1696: Phase II trial of multi-epitope peptide vaccination for melanoma with MGT (MART-1 (27-35), gp100 (209-217, 210M) and tyrosinase (368-376, 370D))+/- IFN alfa-2b and GM-CSF-immunological and clinical results. Proc Am Soc Clin Oncol 22:709, 2003 (abstr)
40. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
41. Weber J: Phase I trial of antibody to CTLA-4 (MDX-010) with melanoma peptides/Ifa for resected stages III/IV melanoma. Proc Am Soc Clin Oncol 22:710, 2003 (abstr)
42. Belli F, Testori A, Rivoltini L, et al: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 20:4169-4180, 2002
43. Sharma R: Tolerability of the novel oral thalidomide analog CC-5013 demonstrating extensive immune activation and clinical response. Proc Am Soc Clin Oncol 22:712, 2003 (abstr)